This biopharmaceutical company has seen one negative estimate revision in the last 30 days. The Zacks Consensus Estimate has also moved lower over the same time frame. This implies trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday’s rally can last.
Retrophin currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Investors interested in the biomedical industry may consider better-ranked stocks like Myriad Genetics Inc. (MYGN), Gilead Sciences Inc. (GILD) and Illumina Inc. (ILMN). All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment